2:10 PM
 | 
May 16, 2018
 |  BC Extra  |  Company News

Priority Review for Insmed’s ALIS in rare lung infection

Insmed Inc. (NASDAQ:INSM) said FDA accepted and granted Priority Review to an NDA for ALIS (amikacin liposome inhalation suspension) to...

Read the full 77 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >